44 results
8-K
EX-99.1
DMAC
DiaMedica Therapeutics Inc.
7 Aug 24
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
4:32pm
incurred in connection with the Company’s lawsuit against PRA Netherlands, partially offset by increased personnel costs incurred in conjunction
8-K
EX-99.1
DMAC
DiaMedica Therapeutics Inc.
19 Mar 24
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
4:16pm
ended December 31, 2022. This increase was primarily driven by increased legal fees incurred in connection with the Company’s lawsuit against
8-K
EX-99.1
umzg6aixhesch j4l
13 Nov 23
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
4:52pm
8-K
EX-10.2
zr2wjopm mr
5 Sep 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
jfj9mhoj7iu9s 7zul
14 Aug 23
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
hpofvb hmze4wnpkvk9r
15 May 23
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
4:31pm
8-K
EX-10.1
old2i7ufjio4
25 May 22
Departure of Directors or Certain Officers
4:49pm
8-K
EX-1.1
924mu1k3ej75jxn8teb
10 Aug 20
DiaMedica Announces Pricing of $20 Million Public Offering of Common Shares
12:00am